Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases.
Bacteremia
Dalbavancin
Endocarditis
Intravascular infection
LVAD
Suppressive therapy
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
26
05
2020
accepted:
14
09
2020
pubmed:
24
9
2020
medline:
3
8
2021
entrez:
23
9
2020
Statut:
ppublish
Résumé
We present four cases with Gram-positive bacteremia (pathogens: MRSA n = 1, Enterococcus spp. n = 3) due to an intravascular source (left ventricular assist device: n = 2, transfemoral aortic valve implantation n = 1, prosthetic aortic valve: n = 1) where no curative treatment was available. These patients received indefinite, chronic suppressive (palliative) therapy with dalbavancin (500 mg weekly or 1000 mg biweekly regimens). Outcomes and clinical characteristics are described; treatment was effective in suppression of bacteremia in all patients over several months (range: 1 to more than 12 months), we observed no relevant side effects.
Identifiants
pubmed: 32965641
doi: 10.1007/s15010-020-01526-0
pii: 10.1007/s15010-020-01526-0
pmc: PMC7850995
doi:
Substances chimiques
Anti-Bacterial Agents
0
Teicoplanin
61036-62-2
dalbavancin
808UI9MS5K
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-186Références
Wunsch S, Krause R, Valentin T, Prattes J, Janata O, Lenger A, et al. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210–4.
doi: 10.1016/j.ijid.2019.02.013
Hakim A, Braun H, Thornton D, Strymish J. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: a case report. Int J Infect Dis. 2020;91:202–5.
doi: 10.1016/j.ijid.2019.12.008
Scott LJ. Dalbavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75:1281–91.
doi: 10.1007/s40265-015-0430-x
Kishor K, Dhasmana N, Kamble S, Sahu R. Linezolid induced adverse drug reactions—an update. Curr Drug Metab. 2015;16:553–9.
doi: 10.2174/1389200216666151001121004
Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis. 2018;67:795–8.
doi: 10.1093/cid/ciy279
Spaziante M, Franchi C, Taliani G, D’Avolio A, Pietropaolo V, Biliotti E, et al. Serum bactericidal activity levels monitor to guide intravenous dalbavancin chronic suppressive therapy of inoperable staphylococcal prosthetic valve endocarditis: a case report. Open Forum Infect Dis. 2019;6:ofz427.
doi: 10.1093/ofid/ofz427
Howard-Anderson J, Pouch SM, Sexton ME, Mehta AK, Smith AL, Lyon GM, et al. Left ventricular assist device infections and the potential role for dalbavancin: a case report. Open Forum Infect Dis. 2019;6:ofz235.
doi: 10.1093/ofid/ofz235
Ciccullo A, Giuliano G, Segala FV, Taddei E, Farinacci D, Pallavicini F. Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection. Infection. 2020;48:309–10.
doi: 10.1007/s15010-019-01379-2
Knafl D, Tobudic S, Cheng SC, Bellamy DR, Thalhammer F. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis. 2017;36:677–80.
doi: 10.1007/s10096-016-2845-z
Tobudic S, Forstner C, Burgmann H, Lagler H, Steininger C, Traby L, et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection. 2019;47:1013–20.
doi: 10.1007/s15010-019-01354-x
Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Dávila P, Iftimie S, Sequera S, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18:30.
doi: 10.1186/s12941-019-0329-6
Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380:415–24.
doi: 10.1056/NEJMoa1808312